Piper Sandler Reiterates Buy Rating on Globus Medical
Piper Sandler maintains its buy rating for Globus Medical with a $100 price target, a 32.59% upside from the current price.
Key Points
- Piper Sandler reiterated its buy rating on Globus Medical, Inc. (NYSE:GMED) with a $100 price target on June 15, 2026.
- Piper Sandler's $100 price target implies 32.59% upside from Globus Medical, Inc.'s ($GMED) current $75.42 share price.
- Globus Medical's stock is trading at $80.39, with a market cap of $10.91 billion and a P/E ratio of 18.78.
- Recent insider activity includes both buying and selling, with notable transactions by David Davidar and Ann Rhoads.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 15, 2026, Piper Sandler reiterated its buy rating on Globus Medical, Inc. (NYSE:GMED), maintaining a price target of $100. The analyst, Matt O'Brien, continues to see potential in the company's stock, which is currently trading at $80.39.
What Changed in Piper Sandler's Globus Medical Position
Piper Sandler's latest move is a reaffirmation of its positive outlook on Globus Medical. The buy rating suggests confidence in the company's future performance, with the target price set at $100, indicating room for growth from its current trading level.
Other Institutional Activity in Globus Medical
Several other institutional investors have made moves in Globus Medical recently. BlackRock, Inc. increased its holdings by 213,321 shares, now owning 10,497,414 shares valued at approximately $904.46 million. Janus Henderson Group PLC also added 328,217 shares, bringing its total to 7,623,095 shares worth about $656.83 million. Meanwhile, Invesco Ltd. boosted its position by 430,249 shares, resulting in a total of 4,316,654 shares valued at $371.92 million.
Globus Medical, Inc. Stock Down 9.1%
Shares of NYSE:GMED are trading near $80.39. Globus Medical has a market cap of approximately $10.91 billion, a P/E ratio of 18.78, and a forward P/E of 15.61. The stock's 52-week range is between $51.79 and $101.40, with a 50-day moving average of $85.95 and a 200-day moving average of $80.58. The company's beta is 0.95, indicating moderate volatility compared to the market.
Recent Earnings
Globus Medical reported revenues of $3.10 billion, reflecting a growth rate of 27%. The company achieved a net margin of 18.92% and a return on equity of 13.30%. Earnings per share stand at $4.28. The next earnings release is scheduled for August 6, 2026.
Insider Buying and Selling at Globus Medical, Inc.
Recent insider transactions at Globus Medical include both buying and selling. On June 5, 2026, David Davidar sold 25,000 shares at an average price of $80.76, while also purchasing 25,000 shares at $26.27. Ann Rhoads bought 25,000 shares at $26.27 on June 4, 2026. Additionally, Kelly Huller, EVP and Corporate Secretary, sold 20,000 shares at $94.50 on February 25, 2026.
Analysts Set New Price Targets
On June 15, 2026, Piper Sandler maintained its buy rating on Globus Medical with a $100 price target. Other analysts, including RBC Capital and Wells Fargo, have also maintained buy ratings with targets of $120 and $103, respectively, on May 8, 2026. The consensus among 11 analysts is a buy recommendation, with a mean target price of $110.
About Globus Medical
Globus Medical, Inc., headquartered in Audubon, Pennsylvania, is a leader in medical devices, focusing on solutions for musculoskeletal disorders. They provide a wide range of products, including spine and orthopedic trauma solutions, robotic surgical systems, and biologics. Founded in 2003, the company aims to enhance patient care through innovative technologies.
Bottom Line
Piper Sandler's reaffirmation of a buy rating with a $100 target for Globus Medical highlights continued confidence in the company's prospects. With a strong market position and innovative product offerings, Globus Medical remains a company to watch. It's important to remember that these analyst ratings are based on past performance and may not reflect future results.
Get Globus Medical, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GMED, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.